Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 10/20 | 0.44 |
| ▸ | HTR2C | P28335 | 10/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2765682 | 1.00 | IDO1 (0.50) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL29447941 | 1.00 | IDO1 (0.50) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL29886684 | 0.87 | IDO1 (0.47) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL81791 | 0.87 | IDO1 (0.47) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL7700904 | 0.85 | IDO1 (0.58) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL17858489 | 0.85 | IDO1 (0.46) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL5038446 | 0.84 | IDO1 (0.52) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL18007006 | 0.84 | IDO1 (0.44) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL7769791 | 0.84 | MAOB (0.41) | IDO1AGXTDAOHTR2AHTR2C | |
| SCHEMBL27830893 | 0.82 | DPP4 (0.43) | IDO1AGXTHTR2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| EP-3966199-B1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2026-03-18 | — | — | EP | disclosed |
| EP-3436445-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20220213058-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2022-07-07 | — | — | US | disclosed |
| CN-114174263-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2020229968-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2020-11-19 | — | — | WO | disclosed |
| EP-3436445-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2019-02-06 | — | — | EP | disclosed |
| US-10174003-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180118720-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-9896436-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20030203889-A1 | Phenylsulphonyl derivatives as 5-HT receptor ligands | MERCK & CO., INC. | 2003-10-30 | — | — | US | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6559166-B1 | A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore | MERCK SHARP & DOHME LTD. | 2003-05-06 | — | — | US | disclosed |
| CN-1399639-A | Novel oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-02-26 | — | — | CN | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-1147084-A1 | PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000043362-A1 | PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2000-07-27 | — | — | WO | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | IDO1 8/4885AGXT 3105/4885DAO 217/4885 |
| US-10174003-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM3B | IDO1 208/4885AGXT 3335/4885DAO 1755/4885 |
| US-20220213058-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | IDO1 2392/4885AGXT 382/4885DAO 769/4885 |
| US-20180118720-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | IDO1 208/4885AGXT 3335/4885DAO 1755/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | IDO1 347/4885AGXT 3763/4885DAO 427/4885 |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | IDO1 2074/4885AGXT 838/4885DAO 585/4885 |
| US-20030203889-A1 | Phenylsulphonyl derivatives as 5-HT receptor ligands | HTR2A, HTR5A, HTR2C | IDO1 591/4885AGXT 4755/4885DAO 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.